Literature DB >> 6652609

Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report.

R Yassa, D Dupont.   

Abstract

Carbamazepine has been used in the treatment of temporal lobe epilepsy since 1963. It has also been found effective in the treatment of psychiatric disorders accompanying epilepsy. Patients with nonspecific EEG abnormalities without overt epilepsy but with behavioral problems, including gross psychopathology and violent behavior, improve on carbamazepine. These findings prompted us to use it in the treatment of aggressive behavior in a schizophrenic patient. Due to the frequency and severity of aggressive behavior in this patient, maintenance ECT was given. However, when carbamazepine was instituted, ECT was discontinued and the patient has been virtually free from aggressive behavior since this medication has been instituted. The authors conclude that carbamazepine may be used in the treatment of aggressive behavior in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652609     DOI: 10.1177/070674378302800712

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  4 in total

Review 1.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  Clinical and demographic characteristics of 15 patients with repetitively assaultive behavior.

Authors:  J W Barber; P Hundley; E Kellogg; J L Glick; L Godleski; R Kerler; W V Vieweg
Journal:  Psychiatr Q       Date:  1988

Review 3.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

Review 4.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.